Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Reports & Briefings
Intellectual Property Chapter and the Impact on Access to Medicines
Last updated 30 November 2016
Briefing: TB - An overview of MSF’s programmatic use and clinical research with new TB treatment regimens
This briefing paper focuses on the critical area of treatment for DR-TB. It provides an overview of the work of Médecins Sans Frontières/Doctors Without Borders (MSF) and its partners, including national ministries of health, in accelerating urgently-needed patient-centered research to improve the quality and availability of treatment regimens for DR-TB.
South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world. In 2015, almost 300,000 people were diagnosed with TB in South Africa, including 20,000 with some form of DR-TB. This briefing document examines the current DR-TB treatment, the role of delamanid in DR-TB treatment, and barriers to accessing delamanid in South Africa.
Last updated 25 October 2016
The Regional Comprehensive Economic Partnership (RCEP) trade agreement is being negotiated in secret, without input from public health stakeholders. A leaked draft of the negotiating text has revealed some proposed provisions that could undermine access to price-lowering, generic medicines, and thus, life-saving treatment to millions of people in the developing world.
Last updated 14 October 2016
In this report, published by the Fix the Patent Laws campaign, of which MSF is a member, nine case studies are presented that demonstrate how systemic shortcomings in South Africa’s patent laws negatively impact on access to medicines to treat a wide range of diseases in both the public and private sectors.
Last updated 27 September 2016
Wambo.org, launched this year by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), is described as “a global marketplace offering a growing range of quality-assured, lifesaving medicines and health-related commodities at competitive, transparent prices.” Under development by the Global Fund since October 2014, it is already available to Global Fund grant recipients with a stated aim of being made available to public health partners.
Last updated 14 September 2016
We could have the vaccines, tests and medicines that we need, and they could be affordable. But today, many of the tools we need are too expensive, and many needs remain unaddressed by medical research. Governments provide billions of taxpayer dollars for medical research. They have the right - and the duty - to ensure that the money is used to meet people’s health needs.
Last updated 14 September 2016
The Trans-Pacific Partnership (TPP) trade deal is currently under consideration by the US and eleven other Pacific Rim nations: Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. The agreement is slated to further expand its membership, potentially to all 21 Asia Pacific APEC nations.
Last updated 9 September 2016
In May 2016 the ‘Review on Antimicrobial Resistance’, commissioned by the government of the United Kingdom and the Welcome Trust, was published by the AMR Review team lead by lord Jim O'Neill. The review set out nine broad recommendations for government intervention to tackle antimicrobial resistance (AMR).
Last updated 22 July 2016
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expanding access to affordable antiretroviral therapy (ART).
Last updated 15 July 2016